Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
StrykerLTS:0R2S +1.01%93 EBIT per Share is $13.58 as of Mar. 2026. GuruFocus rates LTS:0R2S with a GF Score™ of 93/100 and a GF Value™ of $416.00 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 688 Medical Devices & Instruments companies, Stryker ranks better than 60.76% on this metric.
Stryker's EBIT per Share for the
three
months ended in Mar. 2026 was $2.58.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $13.58.
During the past 12 months, the average EBIT per Share Growth Rate of Stryker was 12.10% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 17.20% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 18.20% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 8.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Stryker's EBIT per Share or its related term are showing as below:
LTS:0R2S'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -3.2 Med: 15.3 Max: 40.4
Current: 17.2
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Stryker was 40.40% per year. The lowest was -3.20% per year. And the median was 15.30% per year.
LTS:0R2S's 3-Year EBIT Growth Rate is ranked better than 60.76% of 688
companies
in the Medical Devices & Instruments industry
Industry Median: 9.5
vs LTS:0R2S: 17.20
Stryker's EBIT for the
three
months ended in Mar. 2026 was $998 Mil.
Stryker (LTS:0R2S) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Stryker EBIT per Share Related Terms
Stryker EBIT per Share Historical Data
* Premium members only.
The historical data trend for Stryker's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $13.58
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stryker (LTS:0R2S) has a EBIT per Share of $13.58 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Stryker and its competitors. According to the industry distribution chart, Stryker ranks #270 out of 688 companies in the Medical Devices & Instruments industry, placing it in the top 39.2%.
Is Stryker's EBIT per Share too high?
Stryker's current EBIT per Share is $13.58. The Medical Devices & Instruments industry median EBIT per Share is 9.50. Stryker's value of $13.58 is 42.9% above this industry median. Based on the distribution chart, Stryker ranks #270 out of 688 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Stryker has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Stryker's EBIT per Share compare to MDT and ABT?
According to the Medical Devices & Instruments industry distribution chart, Stryker ranks #270 out of 688 companies for EBIT per Share. This puts Stryker in the upper half of its industry. The industry median EBIT per Share is 9.50. Stryker's value of $13.58 is 42.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.50, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Stryker's current EBIT per Share of $13.58 is 42.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Stryker and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stryker's current EBIT per Share is $13.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stryker stock overvalued right now?
Based on GuruFocus' analysis, Stryker (LTS:0R2S) is currently considered Modestly Undervalued. The stock's GF Value™ is $416.00, compared to a current price of $333.78 — trading 19.8% below its estimated fair value. The current EBIT per Share is $13.58 and 42.9% above the Medical Devices & Instruments industry median of 9.50. Stryker's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Stryker (LTS:0R2S), the current EBIT per Share is $13.58 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stryker (LTS:0R2S) Overvalued in 2026?
Based on GuruFocus' analysis, Stryker stock appears to be undervalued.
The current stock price of $333.78 is trading 19.8% below its estimated GF Value™ of $416.00.
GuruFocus considers Stryker to be Modestly Undervalued.
Key valuation signals for LTS:0R2S:
EBIT per Share: $13.58
GF Value™: $416.00 vs. price of $333.78 (19.8% below fair value)
Industry Position: 42.9% above the Medical Devices & Instruments median (#270 of 688)
No single metric tells the full story. See the LTS:0R2S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.
93GF Score
Get the complete analysis for LTS:0R2S
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0R2S has been successfully added to your 
